CA9 and clear cell renal carcinoma: In 2006, Lamers et al. initiated a phase I clinical trial of CAR-T cell immunotherapy targeting carbonic anhydrase IX (CAIX) for the treatment of clear cell renal cell carcinoma, which verified the feasibility of CAIX as a target for solid tumor treatment and was one of the early explorations of CAR-T cells for solid tumor treatment.